NASDAQ:RUBY - Rubius Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 518.05 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.81
▲ +0.01 (1.25%)

This chart shows the closing price for RUBY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rubius Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RUBY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RUBY

Analyst Price Target is $5.00
▲ +518.05% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Rubius Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $8.00 and a low forecast of $3.00. The average price target represents a 518.05% upside from the last price of $0.81.

This chart shows the closing price for RUBY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Rubius Therapeutics. This rating has held steady since March 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/16/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/17/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/16/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/15/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2022HC WainwrightLower Price Target$15.00 ➝ $8.00High
4/11/2022SVB LeerinkLower Price TargetMarket Perform$5.00 ➝ $3.00High
4/11/2022Morgan StanleyLower Price TargetEqual Weight$15.00 ➝ $4.00High
4/11/2022GuggenheimLower Price TargetBuy$25.00 ➝ $5.00High
4/11/2022HC WainwrightLower Price TargetBuy$40.00 ➝ $15.00High
2/25/2022SVB LeerinkLower Price TargetMarket Perform$14.00 ➝ $5.00High
1/3/2022GuggenheimLower Price Target$32.00 ➝ $25.00Medium
12/20/2021SVB LeerinkReiterated RatingHoldHigh
11/9/2021SVB LeerinkLower Price TargetMarket Perform$20.00 ➝ $14.00High
8/10/2021HC WainwrightReiterated RatingBuy$40.00High
5/18/2021Morgan StanleyBoost Price TargetEqual Weight$24.00 ➝ $25.00Medium
4/19/2021Morgan StanleyBoost Price TargetEqual Weight$10.00 ➝ $24.00High
3/15/2021HC WainwrightBoost Price TargetBuy$28.00 ➝ $40.00High
3/15/2021SVB LeerinkBoost Price TargetMarket Perform$4.00 ➝ $20.00High
3/1/2021SVB LeerinkLower Price TargetMarket Perform$5.00 ➝ $4.00N/A
2/23/2021SVB LeerinkReiterated RatingMarket Perform$5.00 ➝ $4.00Low
1/19/2021Morgan StanleyBoost Price TargetEqual Weight$5.00 ➝ $10.00Low
11/11/2020Morgan StanleyBoost Price TargetEqual Weight$4.00 ➝ $5.00Low
10/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralHigh
8/11/2020HC WainwrightReiterated RatingBuy$28.00High
3/13/2020GuggenheimLower Price TargetBuy$23.00 ➝ $11.00High
3/13/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$15.00 ➝ $4.00High
3/13/2020HC WainwrightLower Price TargetBuy$40.00 ➝ $28.00High
3/13/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$19.00 ➝ $4.00High
1/31/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$9.00Medium
11/15/2019HC WainwrightReiterated RatingBuy$40.00High
9/9/2019Robert W. BairdInitiated CoverageUnderperform$4.00 ➝ $4.00High
8/29/2019JPMorgan Chase & Co.Lower Price TargetOverweight$27.00 ➝ $22.00High
6/26/2019HC WainwrightInitiated CoverageBuy ➝ Buy$40.00High
5/30/2019GuggenheimInitiated CoverageBuy$25.00High
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$37.00 ➝ $34.00High
8/13/2018SVB LeerinkInitiated CoverageOutperformHigh
8/13/2018Morgan StanleyInitiated CoverageOverweight$37.00High
8/13/2018JPMorgan Chase & Co.Initiated CoverageOverweightHigh
8/13/2018Jefferies Financial GroupInitiated CoverageBuy$40.00High
(Data available from 8/16/2017 forward)

News Sentiment Rating

-0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/17/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/16/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/18/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
4/17/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/17/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/16/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/16/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
8/15/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Rubius Therapeutics logo
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $0.81
Low: $0.79
High: $0.83

50 Day Range

MA: $0.85
Low: $0.65
High: $1.24

52 Week Range

Now: $0.81
Low: $0.65
High: $24.84

Volume

366,146 shs

Average Volume

396,623 shs

Market Capitalization

$73.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Rubius Therapeutics?

The following sell-side analysts have issued research reports on Rubius Therapeutics in the last twelve months: Guggenheim, HC Wainwright, Morgan Stanley, and SVB Leerink LLC.
View the latest analyst ratings for RUBY.

What is the current price target for Rubius Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Rubius Therapeutics in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 518.0%. HC Wainwright has the highest price target set, predicting RUBY will reach $8.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $3.00 for Rubius Therapeutics in the next year.
View the latest price targets for RUBY.

What is the current consensus analyst rating for Rubius Therapeutics?

Rubius Therapeutics currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RUBY will outperform the market and that investors should add to their positions of Rubius Therapeutics.
View the latest ratings for RUBY.

What other companies compete with Rubius Therapeutics?

How do I contact Rubius Therapeutics' investor relations team?

Rubius Therapeutics' physical mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 679-9600 and its investor relations email address is [email protected] The official website for Rubius Therapeutics is www.rubiustx.com. Learn More about contacing Rubius Therapeutics investor relations.